Trials / Completed
CompletedNCT00892762
Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 434 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand differences in visual function-related patient-reported outcomes between a non-BAK medication (Travoprost APS) and a BAK-preserved medication (XALATAN®) in patients with open-angle glaucoma or ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Travoprost APS 40 micrograms/ml eye drop solution | non-BAK (benzalkonium chloride) medication |
| DRUG | Latanoprost 50 micrograms/ml eye drop solution | BAK-preserved medication |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2009-05-05
- Last updated
- 2014-07-15
Source: ClinicalTrials.gov record NCT00892762. Inclusion in this directory is not an endorsement.